| アブストラクト | OBJECTIVE: This study aimed to analyze the FAERS database to identify adverse event associated with sunitinib to offer valuable insights for the judicious utilization of medication in clinical settings. METHODS: Various disproportionality analysis techniques, such as the reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPN), and multi-gamma Poisson shrinkage (MGPS), were employed to analyze adverse drug reaction (ADR) reports pertaining to sunitinib in the FAERS database from its market introduction up to the first quarter of 2023. Subsequently, a secondary screening process was conducted to identify reliable positive signals. RESULTS: The analysis of sunitinib adverse event signals at the system-organ classification level encompassed 27 organ systems, with gastrointestinal and endocrine disorders emerging as the predominant SOCs. A total of 237 significant adverse events meeting all four algorithms were detected. Notably, this study revealed previously unreported adverse events, including pleural effusion and ascites, while potential adrenal toxicity-related adverse events, highlighted in the drug's specification, were not identified in this analysis. The study examined the relationship between the duration of sunitinib dosing and the onset of adverse events, revealing a median onset of 48 days (IQR, 15-160 days). The findings indicated that a majority of adverse events manifested early in the dosing period, with tumor progression, disease progression, and mortality becoming more prevalent after one year of treatment. CONCLUSION: In the clinical utilization of sunitinib, vigilant monitoring of potential adverse reactions is imperative during the initial phase of drug administration. In addition to the documented adverse reactions outlined in the drug specification, healthcare providers should remain attentive to potential adverse reactions such as pleural effusion, ascites, and tumor development. |
|---|
| ジャーナル名 | Heliyon |
|---|
| Pubmed追加日 | 2024/9/19 |
|---|
| 投稿者 | Zou, Wenbin; Yang, Han; Xi, Yu; Zeng, Chenxi; Chen, Wei; Fu, Xiangning |
|---|
| 組織名 | Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong;University of Science and Technology, 1095 Jiefang Avenue, Qiaokou District,;Wuhan, Hubei Province, 430000, China.;Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong;University of Science and Technology, 1277 Jiefang Avenue, Jianghan District, |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/39296163/ |
|---|
